Dec 30 (Reuters) - Sangamo Therapeutics SGMO.O said on Monday it would regain full rights to its hemophilia A gene therapy after co-development partner Pfizer PFE.N terminated the agreement.
(Reporting by Puyaan Singh in Bengaluru; Editing by Mohammed Safi Shamsi)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.